| Literature DB >> 27375583 |
Gurmeet Kaur1, P Balamurugan1, C Uma Maheswari2, A Anitha2, S Adline Princy1.
Abstract
Dental caries occur as a result of disequilibrium between acid producing pathogenic bacteria and alkali generating commensal bacteria within a dental biofilm (dental plaque). Streptococcus mutans has been reported as a primary cariogenic pathogen associated with dental caries. Emergence of multidrug resistant as well as fluoride resistant strains of S. mutans due to over use of various antibiotics are a rising problem and prompted the researchers worldwide to search for alternative therapies. In this perspective, the present study was aimed to screen selective inhibitors against ComA, a bacteriocin associated ABC transporter, involved in the quorum sensing of S. mutans. In light of our present in silico findings, 1,3-disubstituted urea derivatives which had better affinity to ComA were chemically synthesized in the present study for in vitro evaluation of S. mutans biofilm inhibition. The results revealed that 1,3-disubstituted urea derivatives showed good biofilm inhibition. In addition, synthesized compounds exhibited potent synergy with a very low concentration of fluoride (31.25-62.5 ppm) in inhibiting the biofilm formation of S. mutans without affecting the bacterial growth. Further, the results were supported by confocal laser scanning microscopy. On the whole, from our experimental results we conclude that the combinatorial application of fluoride and disubstituted ureas has a potential synergistic effect which has a promising approach in combating multidrug resistant and fluoride resistant S. mutans in dental caries management.Entities:
Keywords: Streptococcus mutans; dental caries; fluoride resistant; multidrug resistant; quorum sensing; synergism
Year: 2016 PMID: 27375583 PMCID: PMC4893485 DOI: 10.3389/fmicb.2016.00861
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1(A) Synthesis scheme of 1,3-disubstituted ureas. (B) A thin layer chromatogram showing completion of the reaction (30% Ethyl acetate:Hexane). Spot 1 represents reactant 1 (2,4,6-Trimethyl aniline), spot 2 represents (4-nitrophenyl isocyanate), and P represents their corresponding product (1-mesityl-3-(4-nitrophenyl)urea). The difference in the Rf values and color change of reactants to products indicates the completion of reaction.
Final selected ligands after TOPKAT and ADMET properties as ComA inhibitors.
| 1 | −3.915 | 336.84 | Q11, R93, L94 | |
| 2 | −3.128 | 335.32 | Q11 | |
| 3 | −3.433 | 307.34 | H96, Q95, R93 | |
| 4 | −3.532 | 318.25 | H96, R93, L94 | |
| 5 | −3.088 | 240.30 | Q11 | |
| 6 | −4.034 | 294.33 | Q11 | |
| 7 | −3.579 | 322.75 | H96, Q95, R93 |
Schematic representation of ADMET and TOPKAT properties of ComAI and its derivatives.
| ComAI | −3.088 | 100 | |||||
| Derivatives of ComAI | |||||||
| ComAI1 | −3.815 | 100 | |||||
| ComAI2 | −3.334 | 100 | |||||
| ComAI3 | −3.214 | 86.7 | |||||
| ComAI4 | −3.342 | 100 | |||||
| ComAI' | −0.485 | – | |||||
.
Figure 2(A) Binding of ComAI with PEP domain of ComA through Hydrogen bonding (yellow dotted line). (B) Schematic 2D representation of Ligand interaction pattern of ComAI (ComA Inhibitor) with PEP domain of ComA.
Figure 3Schematic 2D representation of interaction of derivatives of ComAI with PEP domain of ComA. (A) ComAI1; (B) ComAI2; (C) ComAI3; (D) ComAI4.
Structures of reactants and their corresponding products.
| ComAI | |||
| ComAI1 | |||
| ComAI2 | |||
| ComAI3 | |||
| ComAI4 | |||
| ComAI1′ |
IC.
| ComAI | 3.75 | 13.5 | – | – | 14.9 | – | – | – | 0.39 | 7.5 | – | – | – | 14.8 | – | – |
| ComAI1 | 1.89 | 12.2 | – | – | – | – | – | – | 0.89 | – | – | – | – | 12.4 | – | – |
| ComAI2 | – | 13 | – | – | 11.5 | – | – | – | 1.78 | – | – | – | – | 15 | – | – |
| ComAI3 | 4.22 | 14.9 | – | – | – | – | – | – | – | – | – | – | – | 13.8 | – | – |
| ComAI4 | – | – | – | – | 0.46 | 14 | – | – | 0.41 | 14.5 | – | – | – | 14.5 | – | – |
| ComAI1′ | – | – | – | – | 14.7 | – | – | – | – | 13.5 | – | – | – | 11.5 | – | – |
IC, inhibitory concentration; EC, Eradication Concentration.
Strains used: MTCC 497, standard reference strain obtained from MTCC, IMTECH, Chandigarh, India; WT, A wild type strain obtained from kindly donated by Prof. L. Jeannine Brady, University of Florida, USA.; 4SM, Multidrug resistant clinical isolate; 5SM, Fluoride resistant clinical isolate.
Synergistic activity of selected ligands with Fluoride (F) and Chlorhexidine (CHX).
| MTCC 497 | FIC | 0.2 (0.05–0.48) | 2.8 (1.4–4.0) | 0.39 (0.05–0.40) | 2.6 (1.6–5.0) | 0.05 (0.01–0.17) | 3.5 (2.7–5.9) | 0.05 (0.02–0.19) | 3.8 (2.0–7.1) | – | – | – | – |
| I | SYN | NI/ANT | SYN | NI/ANT | SYN | ANT | SYN | ANT | – | – | |||
| WT | FIC | 0.01 (0.01–0.05) | 0.6 (0.5–2.2) | – | – | 0.02 (0.01–0.03) | 0.6 (0.5–1.4) | – | – | 0.02 (0.02–0.04) | 0.6 (0.5–2.4) | 0.02 (0.01–0.02) | 0.6 (0.5–2.7) |
| I | SYN | ADD/NI | – | – | SYN | ADD | – | – | SYN | ADD/NI | SYN | ADD/NI | |
| 4SM | FIC | 1.1(0.7–1.45) | 2.7 (0.6–4.5) | 0.52 (0.5–0.6) | 2.4 (0.5–4.2) | 0.28 (0.28–0.32) | 2.2 (0.6–3.9) | – | – | 2.41 (2.1–2.5) | 3.7 (1.1–6.5) | 0.03 (0.03–0.05) | 1.5 (1.2–2.7) |
| I | ADD | ADD/ANT | ADD | ADD/ANT | ADD | ADD/ANT | – | – | IND | NI/ANT | SYN | NI/ANT | |
| 5SM | FIC | 0.08 (0.02–0.1) | 9.8 (2.0–19.7) | 0.2 (0.02–0.1) | 10 (2.6–18.5) | 0.2 (0.1–0.3) | 11.6 (3.7–23.4) | 0.08 (0.02–0.1) | 11.2 (3.2–25.0) | 0.09 (0.02–0.15) | 13.7 (6.8–23.5) | 0.08 (0.02–0.12) | 15.3 (7.8–24.7) |
| I | SYN | ANT | SYN | NI/ANT | SYN | ANT | SYN | ANT | SYN | ANT | SYN | ANT |
FIC model -FIC Index of ≤ 0.5 was defined as synergy (SYN), FICI of >4.0 was defined as antagonism (ANT), and indifference [i.e., no interaction (NI) or Additive effect (ADD)] as a FICI of >0.5–4; I corresponds to Interpretation in the above table.
Delta E model of selected compounds with Fluoride (F) and Chlorhexidine (CHX).
| MTCC 497 | ΔE | 1426 | −393 | 1736 | −114 | 1771 | −531 | 1218 | −307 | – | – | – | – |
| I | SS | SA | SS | MA | SS | SA | SS | SA | – | – | |||
| WT | ΔE | 1467 | 44 | – | – | 1222 | 22 | – | – | 1584 | 84 | 1730 | 30 |
| I | SS | WS | – | – | SS | WS | – | – | SS | WS | SS | WS | |
| 4SM | ΔE | 98 | −329 | 55 | −521 | 78 | −283 | – | – | 87 | −489 | 1861 | −462 |
| I | WS | SA | WS | SA | WS | SA | – | – | WS | SA | SS | SA | |
| 5SM | ΔE | 1548 | −378 | 1120 | −241 | 1004 | −283 | 1217 | −228 | 1725 | −532 | 1939 | 625 |
| I | SS | SA | SS | SA | SS | SA | SS | SA | SS | SA | SS | SA | |
SS, Strong Synergism; SA, Strong Antagonism; WS, Weak Synergism; MA, Moderate Antagonism.
Figure 4Effect of ComAI treatments alone as well as in synergy on . Live/Dead staining of bacterial biofilm observed under confocal laser scanning microscopy (green color-Syto 9). (A) Control biofilm, (B) ComAI treated biofilm (3.75 μM), (C) Fluoride treated biofilm (500 ppm), (D) Synergistic activity of ComAI and fluoride (31.25 ppm fluoride and 3.75 μM ComAI).
Figure 5Effect of ComAI treatments alone as well as in synergy on . Live/Dead staining of bacterial biofilm observed under confocal laser scanning microscopy (green color-Syto 9). (A) Control biofilm, (B) ComAI treated biofilm (15 μM), (C) Fluoride treated biofilm (500 ppm), (D) Synergistic activity of ComAI and fluoride (31.25 ppm fluoride and 15 μM ComAI).